PDCD1 and hepatocellular carcinoma: This multicenter retrospective study aimed to evaluate the efficacy and safety of PA-HAIC combined with lenvatinib and PD-1 inhibitors versus PA-HAIC plus lenvatinib alone in patients with solitary large HCC after curative resection.